Regulatory T Cell Marker Detection for DMARD Response Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for determining the effectiveness of Disease Modifying Anti-Rheumatic Drug (DMARD) therapy in rheumatoid arthritis are unreliable and time-consuming, leading to prolonged periods of poorly controlled disease and increased risk of irreversible joint damage.
Innovation Solution
A method for predicting responsiveness to DMARD therapy by detecting specific markers such as regulatory T cells with CD45RA+FoxP3− and CD45RA−FoxP3+ phenotypes in biological samples, correlating their levels to predicted treatment response, using techniques like flow cytometry and antibody labeling.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If composite disease activity scores such as DAS28 are used to monitor treatment response, then disease activity can be tracked, but the measurement reliability is poor due to non-specific markers and subjective components
Solution Approach 1:
The patent extracts and measures specific immune cell populations (Tregs, Teffs, monocytes) and their markers separately from the composite DAS28 score. By isolating these specific cellular components and their phenotypic markers, the method achieves more reliable and precise measurements of immune response to DMARD therapy, avoiding the non-specificity and subjectivity of composite scores.
Solution Approach 2:
The patent introduces flow cytometry as an intermediary measurement technique that objectively quantifies immune cell populations and their markers. This intermediary method provides precise, objective data on immune cell changes in response to treatment, mediating between the clinical need for reliable monitoring and the limitations of subjective clinical assessments.
2Loss of time
If standard DMARD therapy monitoring is used, then treatment can be administered, but the time to determine treatment effectiveness is prolonged (3-6 months)
Solution Approach 1:
The patent performs preliminary measurement of immune cell populations and their phenotypic markers before and during early DMARD treatment. By establishing baseline immune cell profiles and monitoring early changes in these specific cellular parameters, the method can predict treatment effectiveness earlier than standard clinical outcomes, reducing the time to determine whether a treatment is working while maintaining reliable assessment through objective flow cytometry measurements.
3Measurement precision
If prolonged monitoring periods are used to assess DMARD effectiveness, then more accurate treatment response can be determined, but the risk of irreversible joint damage increases during the monitoring period
Solution Approach 1:
The patent performs preliminary assessment of immune cell populations and their phenotypic markers to predict treatment effectiveness before prolonged exposure to ineffective therapy occurs. By measuring baseline immune cell profiles and early changes in response to treatment, clinicians can identify non-responders earlier and switch therapies before irreversible joint damage accumulates during prolonged monitoring periods.
Solution Approach 2:
The patent accelerates the assessment process by using flow cytometry to rapidly quantify immune cell populations and their markers, providing treatment response information much faster than standard clinical monitoring. This allows clinicians to skip the prolonged waiting period and make timely treatment decisions, reducing the time patients spend on ineffective therapy and minimizing joint damage risk.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables earlier identification of treatment responsiveness, reducing the time to optimal treatment regimens, minimizing exposure to ineffective treatments, and potentially reducing joint damage and treatment costs.
Implementation Method 1
detecting the presence, absence, or quantitative level of a first marker in a biological sample; detecting the presence, absence or quantitative level of a second marker in the biological sample
Implementation Method 2
using techniques like flow cytometry and antibody labeling
Data Source
AI summary
This invention relates to predicting a subject's responsiveness to Disease Modifying Anti-Rheumatic Drug therapy of rheumatoid arthritis. The invention provides an in vitro method for predicting responsiveness to a Disease Modifying Anti-Rheumatic Drug therapy in a subject, the method comprising the steps of: (a) providing a biological sample; (b) detecting the presence, absence, or quantitative level of a first marker in the biological sample, wherein the first marker is a regulatory T cell having a CD45RA+FoxP3− phenotype; (c) correlating the presence, absence, or quantitative level of the first marker to the predicted responsiveness to the Disease Modifying Anti-Rheumatic Drug therapy in the subject.